Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Profound Medical (PROF) Net Income towards Common Stockholders (2019 - 2026)

Profound Medical has reported Net Income towards Common Stockholders over the past 7 years, most recently at $77.0 million for Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders rose 51.85% year-over-year to $77.0 million; the TTM value through Dec 2025 reached $42.6 million, up 53.04%, while the annual FY2025 figure was $42.6 million, 53.04% up from the prior year.
  • Net Income towards Common Stockholders for Q4 2025 was $77.0 million at Profound Medical, up from -$8.0 million in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at $77.0 million in Q4 2025 and troughed at -$51.0 million in Q4 2021.
  • A 5-year average of -$842750.0 and a median of $5.2 million in 2022 define the central range for Net Income towards Common Stockholders.
  • On a YoY basis, Net Income towards Common Stockholders climbed as much as 206.21% in 2024 and fell as far as 269.41% in 2024.
  • Year by year, Net Income towards Common Stockholders stood at -$51.0 million in 2021, then increased by 6.97% to -$47.4 million in 2022, then decreased by 0.59% to -$47.7 million in 2023, then surged by 206.21% to $50.7 million in 2024, then soared by 51.85% to $77.0 million in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for PROF at $77.0 million in Q4 2025, -$8.0 million in Q3 2025, and -$15.7 million in Q2 2025.